Parabilis Medicines, Inc.
PBLS
$38.76
-$1.01-2.54%
NASDAQ
| 06/30/2026 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Net Income | -15.77% | 9.17% | |||
| Total Depreciation and Amortization | -2.15% | -5.50% | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | 252.88% | 3.21% | |||
| Change in Net Operating Assets | 598.17% | -57.52% | |||
| Cash from Operations | 92.64% | 8.97% | |||
| Capital Expenditure | -66.94% | 78.38% | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -- | 262.66% | |||
| Cash from Investing | -9,131.17% | 266.44% | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | -0.08% | -2.86% | |||
| Issuance of Common Stock | 428,860.96% | -- | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -100.00% | -100.00% | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -105.15% | 100.00% | |||
| Cash from Financing | 126.76% | -100.20% | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 151.56% | -116.86% | |||